• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Cosmetics
  • 14th Five-Year Plan Review for Drugs, Medical Devices and Cosmetics

14th Five-Year Plan Review for Drugs, Medical Devices and Cosmetics

Saturday, 26 February 2022 / Published in Cosmetics, Medical Device, News, NMPA Registration in China, Pharmaceuticals & DMF

14th Five-Year Plan Review for Drugs, Medical Devices and Cosmetics

On December 30, the NMPA (National Medical Products Administration) issued the 14th Five-Year Plan for National Drug Safety and Promotion of High Quality Development. The Five-Year Plan sets goals to (i) achieve high quality industrial production under improved regulatory monitoring; (ii) reach global standard of vaccine regulations; (iii) adopt traditional Chinese medicine in innovative developments; (iv) make vast improvements with professional talents acquisition; and (v) strengthen technical support capabilities.

Highlights

The 13th Five-Year Plan was a success for the following achievements:

  • Implementation of the newly revised law on the supervision and administration of medical devices (Order 739)  and the new administrative measures for the registration and filing of medical devices (No.47-2021) and IVDs (No.48-2021).
  • Introduction of the Cosmetic Supervision and Administration Regulation (CSAR).
  • Implementation of the 2020 edition of the Pharmacopoeia
  • Over 90% of the total medical device regulatory standards published in China aligns with international standards

According to the 14th Five-Year Plan,

  • 2650 standards will be implemented or revised for pharmaceuticals, medical devices and cosmetics whilst 480 technical review guidelines will be added
  • Random inspection will be conducted annually on approximately 50 different categories of medical devices that are considered to be high risk, largely consumed daily, and a  great concern to the community.
  • QMS inspection will be conducted at least once a year for manufacturers producing sterlized and implantable medical device products.
  • 500 medical device regulations will be issued and revised by 2025. Mainly, mandatory standards focusing on health and safety as well as recommended standards for high-quality industrial improvement.
  • Increase registration capability for new innovative drugs and medical devices from overseas to launch simultaneously in China
  • Establish a complete system for better adverse event monitoring and reporting on drugs, medical devices and cosmetics.
  • Keep up with the evolution of global technology by setting up laboraties focusing in the field of artificial intelligence, biological materials and in vitro diagnostic reagents.

By Julie Zhang and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: five-year plan

What you can read next

Public Consultation on the Measures of Review Management on Advertising for Health Food, FSMP, Drug Products and Medical Devices
NMPA Major Updates Concerning IVDs
China Medical Device Clinical Evaluation Recommended Paths
China Medical Device Clinical Evaluation Recommended Paths

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP